Literature DB >> 8582432

Increased urinary excretion of dicarboxylic acids and 4-hydroxyphenyllactic acid in patients with Zellweger syndrome.

E Mayatepek, C K Seppel, G F Hoffmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8582432     DOI： 10.1007/bf02276727

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  9 in total

1.  Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome.

Authors:  S Goldfischer; C L Moore; A B Johnson; A J Spiro; M P Valsamis; H K Wisniewski; R H Ritch; W T Norton; I Rapin; L M Gartner
Journal:  Science       Date:  1973-10-05       Impact factor: 47.728

2.  Screening for organic acidurias and amino acidopathies in newborns and children.

Authors:  R A Chalmers; P Purkiss; R W Watts; A M Lawson
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

3.  Quantitative analysis for organic acids in biological samples: batch isolation followed by gas chromatographic-mass spectrometric analysis.

Authors:  G Hoffmann; S Aramaki; E Blum-Hoffmann; W L Nyhan; L Sweetman
Journal:  Clin Chem       Date:  1989-04       Impact factor: 8.327

4.  The differential diagnosis of dicarboxylic aciduria.

Authors:  M Duran; J B De Klerk; S K Wadman; L Bruinvis; D Ketting
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

5.  Urinary excretion of dicarboxylic acids from patients with the Zellweger syndrome. Importance of peroxisomes in beta-oxidation of dicarboxylic acids.

Authors:  I Björkhem; S Blomstrand; P Hågå; B F Kase; E Palonek; J I Pedersen; B Strandvik; S A Wikström
Journal:  Biochim Biophys Acta       Date:  1984-08-15

6.  A study of urinary metabolites in patients with dicarboxylic aciduria for differential diagnosis.

Authors:  N Shimizu; S Yamaguchi; T Orii
Journal:  Acta Paediatr Jpn       Date:  1994-04

7.  Cyanide-insensitive and clofibrate enhanced beta-oxidation of dodecanedioic acid in rat liver. An indication of peroxisomal beta-oxidation of N-dicarboxylic acids.

Authors:  P B Mortensen; S Kølvraa; N Gregersen; K Rasmussen
Journal:  Biochim Biophys Acta       Date:  1982-11-12

8.  Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders.

Authors:  E Mayatepek; W D Lehmann; J Fauler; D Tsikas; J C Frölich; R B Schutgens; R J Wanders; D Keppler
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

9.  Medium- and long-chain dicarboxylic aciduria in patients with Zellweger syndrome and neonatal adrenoleukodystrophy.

Authors:  F Rocchiccioli; P Aubourg; P F Bougnères
Journal:  Pediatr Res       Date:  1986-01       Impact factor: 3.756
  9 in total
  4 in total

1.  Stereoselective analysis of 2-hydroxysebacic acid in urine of patients with Zellweger syndrome and of premature infants fed with medium-chain triglycerides.

Authors:  A Muth; A Mosandl; R J A Wanders; M J M Nowaczyk; I Baric; H Böhles; A C Sewell
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

2.  Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.

Authors:  Silvia Darb-Esfahani; Elena Ioana Braicu; Mika Hilvo; Ines de Santiago; Peddinti Gopalacharyulu; Wolfgang D Schmitt; Jan Budczies; Marc Kuhberg; Manfred Dietel; Tero Aittokallio; Florian Markowetz; Carsten Denkert; Jalid Sehouli; Christian Frezza
Journal:  Cancer Res       Date:  2015-12-18       Impact factor: 12.701

Review 3.  Mechanisms of innate immunity in C. elegans epidermis.

Authors:  Clara Taffoni; Nathalie Pujol
Journal:  Tissue Barriers       Date:  2015-10-05

4.  Activation of a G protein-coupled receptor by its endogenous ligand triggers the innate immune response of Caenorhabditis elegans.

Authors:  Olivier Zugasti; Neelanjan Bose; Barbara Squiban; Jérôme Belougne; C Léopold Kurz; Frank C Schroeder; Nathalie Pujol; Jonathan J Ewbank
Journal:  Nat Immunol       Date:  2014-08-03       Impact factor: 25.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.